CompletedNot Applicable

Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital

France262 participantsStarted 2015-10

Plain-language summary

The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic, gastro-enterologic or ophthalmic condition

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female over 18 year old * Patient treated with REMICADE® in Cochin hospital * More than 3 perfusions of REMICADE® before the switch to INFLECTRA® Exclusion Criteria: * none

What they're measuring

Percentage of patients continuing INFLECTRA®

Timeframe: after the third infusion of INFLECTRA®, up to 24 weeks

Trial details

NCT IDNCT02998398

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Rheumatoid Arthritis trials